Analyst Price Target is $13.17
▲ +45.17% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for BrainsWay in the last 3 months. The average price target is $13.17, with a high forecast of $16.00 and a low forecast of $11.00. The average price target represents a 45.17% upside from the last price of $9.07.
Current Consensus is
Buy
The current consensus among 3 polled investment analysts is to buy stock in BrainsWay. This rating has held steady since October 2024, when it changed from a Moderate Buy consensus rating.
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
Read More